Deficiency in the activity of the α-Gal A enzyme encoded by the GLA gene, caused by pathogenic mutations that can be found on ClinVar—NCBI and have been identified in patients with Fabry disease (FD), leads to the accumulation of globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3) in various cells throughout the body. Here, GLA is linked to Fabry disease.